Integrating bulk-RNA and single-cell analysis reveals heterogeneous expression of cuproptosis-related sorafenib-resistant genes in hepatocellular carcinoma DOI Creative Commons

Ziqian Yu,

Linnan Song,

Yuhao Wang

и другие.

ONCOLOGIE, Год журнала: 2024, Номер 26(5), С. 783 - 797

Опубликована: Июль 29, 2024

Abstract Objectives Cuproptosis represents the copper-dependent novel cell death pattern. However, effects of cuproptosis-related sorafenib-resistant genes on prognosis, treatment response, and sorafenib resistance in hepatocellular carcinoma (HCC) patients are still unclear. The present work aims to develop a signature for predicting HCC prognosis. Methods Cuproptosis-related differentially expressed (CRSRDEGs) were identified by correlation analysis between cuproptosis using electronic databases TCGA GEO. Besides, risk score model (CRSRRSM) was established through LASSO univariate Cox regression analyses. Later, this adopted analyzing patient Certain potential drugs sensitivity also analyzed receiving or transarterial chemoembolization (TACE) treatment. Results CRSRRSM achieved excellent efficiency prognosis TACE response patients. As revealed somatic mutational analyses, associated with tumor burden (TMB), especially TP53, CSMD3, OBSCN mutations. According functional enrichment analysis, closely correlated tumor-related pathways, tricarboxylic acid (TCA) cycle, drug resistance. Notably, such as sepantronium bromide, AZD8055, RO-3306, promising alternatives treating resistance, proposed based CRSRRSM. Furthermore, single-cell transcriptomic that high-risk malignant cells demonstrated an increased capacity proliferation immune evasion. Conclusions A model, designated CRSRRSM, constructed can effectively predict This provides implications clinical management

Язык: Английский

Accumulation of microtubule-associated protein tau promotes hepatocellular carcinogenesis through inhibiting autophagosome-lysosome fusion DOI
Xuemin Liu,

Zhiwei Hao,

Huanhuan He

и другие.

Molecular and Cellular Biochemistry, Год журнала: 2024, Номер unknown

Опубликована: Дек. 24, 2024

Язык: Английский

Процитировано

3

IL-2-loaded liposomes modified with sorafenib derivative exert a synergistic anti-melanoma effect via improving tumor immune microenvironment and enhancing antiangiogenic activity DOI Creative Commons
Xuan Huang,

Kudelaidi Kuerban,

J P Fan

и другие.

Asian Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер unknown, С. 101020 - 101020

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

Application of multi-omics in hepatocellular carcinoma: new prospects for classification and precise diagnosis and treatment DOI Open Access

Jiaxue He,

Xintong Hu,

Liguo Chen

и другие.

Hepatoma Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 23, 2025

Hepatocellular carcinoma (HCC) represents a significant global health challenge, with complex etiology and limited treatment options. The integration of multi-omics technologies, including genomics, transcriptomics, proteomics, metabolomics, has revolutionized our understanding HCC, offering novel insights into its molecular underpinnings. This comprehensive review synthesizes the current knowledge on application in highlighting role disease classification, early detection, development targeted therapies. We discuss identification key driver mutations single nucleotide polymorphisms (SNPs) that enhance risk prediction models, implications for personalized medicine. approach facilitated discovery distinct HCC subtypes, each unique signatures tumor microenvironments (TME), which are critical predicting prognosis guiding strategies. Furthermore, we explore these findings precision medicine, emphasizing potential biomarker therapies, immune checkpoint blockade (ICB). concludes by underscoring transformative impact research clinical practice, heralding new era medicine promise improved patient outcomes.

Язык: Английский

Процитировано

0

m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy DOI Creative Commons
Yong Li, Qingbin Liu, Xianying Li

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Фев. 17, 2025

Hepatocellular carcinoma (HCC) is the most prevalent primary liver malignancy and a leading cause of cancer-related deaths globally. The asymptomatic progression early-stage HCC often results in diagnosis at advanced stages, significantly limiting therapeutic options worsening prognosis. Immunotherapy, with immune checkpoint inhibitors (ICIs) forefront, has revolutionized treatment. Nevertheless, tumor heterogeneity, evasion, presence immunosuppressive components within microenvironment (TIME) continue to compromise its efficacy. Furthermore, resistance or non-responsiveness ICIs some patients underscores urgent need unravel complexities TIME design innovative strategies that enhance immunotherapeutic outcomes. Emerging evidence revealed pivotal role N6-methyladenosine (m6A), prominent RNA methylation modification, shaping HCC. By regulating stability translation, m6A influences immune-related factors, including cytokines molecules. This modification governs PD-L1 expression, facilitating escape contributing against ICIs. Advances this field have also identified m6A-related regulators as promising biomarkers for predicting immunotherapy response potential targets optimizing treatment review examines regulatory mechanisms HCC, focus on impact cells cytokine dynamics. It explores targeting pathways improve efficacy outlines emerging directions future research. These insights aim provide foundation developing novel overcome advance

Язык: Английский

Процитировано

0

Monitoring Sorafenib Resistance and Efficacy in Hepatocellular Carcinoma Using [18F]Alfatide II and [18F]Fluorodeoxyglucose Positron Emission Tomography DOI
Guanyun Wang, Yue Pan, Lingling Zheng

и другие.

Molecular Pharmaceutics, Год журнала: 2025, Номер unknown

Опубликована: Фев. 23, 2025

Integrin αvβ3 expression is associated with sorafenib resistance in hepatocellular carcinoma (HCC). Therefore, monitoring its HCC may serve as a valuable indicator of the efficacy treatment. In this study, longitudinal positron emission tomography (PET) was performed to assess [18F]Alfatide II and [18F]fluorodeoxyglucose ([18F]FDG) suitable probes for evaluating treatment Huh-7 human (HCC) xenograft model. tumor cells were used establish both normal sorafenib-resistant cell lines, models developed. The mice categorized into four groups based on type treatment: nontreatment, treatment, received intragastric injections (30 mg/kg/day) or vehicle 15 consecutive days. Tumor size weight assessed throughout study. Longitudinal microPET/computed (CT) scans [18F]FDG acquired quantitatively measure angiogenesis days -2, 3, 7, 14 metabolism -1, 4, 8, following therapy initiation. uptake (ID%/gmean) each probe calculated. No significant difference observed between (P = 0.452); however, differed significantly two < 0.001). Sorafenib successfully inhibited growth, inducing differences 9 after 0.05). lesions changed day However, no change > PET imaging data validated through ex vivo immunohistochemistry analysis targeting integrin αvβ3, VEGF, GULT-1. more effective therapeutic model than [18F]FDG.

Язык: Английский

Процитировано

0

Mechanism and Molecular Targets of Euphorbia fischeriana Steud Root Extract in Hepatocellular Carcinoma DOI
Xinchen Tian,

Fen Liu,

Jing Zhao

и другие.

Journal of Ethnopharmacology, Год журнала: 2025, Номер unknown, С. 119707 - 119707

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships DOI Creative Commons
Alma D. Campos-Parra, David Sánchez-Marín, Víctor Acevedo-Sánchez

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(4), С. 492 - 492

Опубликована: Март 28, 2025

Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatments by being less toxic and improving the survival of patients. The greatest challenge to their success is resistance exhibited However, potential microRNAs (miRNAs) for sensitizing molecules TKIs has been well recognized, with several reports publishing promising results. Nonetheless, this therapeutic window faces challenges often-overlooked limitations. One most fundamental selecting optimal miRNA candidates clinical trials, as miRNAs are promiscuous regulate hundreds targets. In review, we describe how enhance sensitivity across various types cancer. We highlight limitations in achieving a successful collaboration between small (TKIs–miRNAs). Our focus on proposing workflow select suitable candidate, recommending available bioinformatics tools develop partnership miRNAs. hope that initial proposal will provide valuable support future research.

Язык: Английский

Процитировано

0

Antitumor effects of dauricine on sorafenib-treated human lung cancer cell lines via modulation of HIF-1α signaling pathways DOI Creative Commons

Eman K Teleb,

Radwa A. Mehanna,

Nagwa M. Assem

и другие.

Medical Oncology, Год журнала: 2025, Номер 42(5)

Опубликована: Апрель 9, 2025

Язык: Английский

Процитировано

0

High Mobility Group Box 1 Is Potential Target Therapy for Inhibiting Metastasis and Enhancing Drug Sensitivity of Hepatocellular Carcinoma DOI Open Access
Arunya Jiraviriyakul,

Chatchai Nensat,

Samitanan Promchai

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(8), С. 3491 - 3491

Опубликована: Апрель 8, 2025

Hepatocellular carcinoma (HCC) is a lethal malignancy associated with drug resistance, resulting in poor prognosis. High mobility group box 1 (HMGB1) chromatin-binding protein that regulates HCC progression. The overexpression of HMGB1 has been found to promote tumorigenesis and resistance. In this study, we aimed investigate the role expression metastasis its impact on sorafenib oxaliplatin Tissue samples from patients (n = 48) were subjected immunohistochemistry. was correlated clinical pathology parameters. Moreover, cell line HuH-7 used study regulatory effect proliferation, adhesion, migration, invasion by using siRNA (small interfering RNA) silencing method. Furthermore, challenges performed determine sensitivity chemotherapeutic drugs (sorafenib oxaliplatin). significantly overexpressed tumor tissues, highlighted increment M1 advanced tumors immunoreactivity scores 2.61 6.50 for adjacent respectively (p-values 0.0035). involved mechanisms then described through suppression silencing. Notably, inhibition promoted sorafenib/oxaliplatin increasing toxicity about 13-18%. Our demonstrated shows potential as promising biomarker target treatment tumorigenesis, metastasis, chemo-drug

Язык: Английский

Процитировано

0

Insights into Sorafenib resistance in hepatocellular carcinoma: Mechanisms and therapeutic aspects. DOI

Eman H. Yousef,

Amal M. El Gayar,

Nada F. Abo El‐Magd

и другие.

Critical Reviews in Oncology/Hematology, Год журнала: 2025, Номер unknown, С. 104765 - 104765

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0